Categorized | Scientific Publications

Melanoma Journal Articles for July 2017

Journal of Clinical Oncology

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial

James LarkinDavid MinorSandra D’AngeloBart NeynsMichael SmylieWilson H. Miller, …

DOI: 10.1200/JCO.2016.71.8023 Journal of Clinical Oncology – published online before print July 3, 2017


Anticancer Research

Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide

 

KAVINDRA NATHDAVID S. NELSONJEFFREY ROMANMARY E. PUTT, SEUNG-CHEOL LEEDENNIS B. LEEPER  and JERRY D. GLICKSON 

  • Received May 10, 2017.
  • Revision received May 24, 2017.
  • Accepted May 25, 2017.

Anticancer Research July 2017 vol. 37 no. 73413-3421


Nivolumab Therapy for Treatment-Related Vitiligo in a Patient With Relapsed Metastatic Melanoma

Yasuhiro Nakamura, MD, PhD1Yukiko Teramoto, MD, PhD1Yuri Asami, MD1; et al

JAMA Dermatol. Published online July 5, 2017. doi:10.1001/jamadermatol.2017.1679


International Journal of Cancer

Menopausal hormone therapy and risk of melanoma: do estrogens and progestins have a different role?

Authors Edoardo Botteri1,2†* , Nathalie C. Støer1†, Solveig Sakshaug3 , Sidsel Graff-Iversen4 , Siri Vangen1,5, Solveig Hofvind6,7, Giske Ursin8,9,10, Elisabete Weiderpass11,12,13,14

Accepted online 7th July 2017


Perioperative BRAF inhibitors in locally advanced stage III melanoma.

Douglas Zippel MD, Gal Markel MD, Roni Shapira-Frommer MD, Guy Ben-Betzalel MD, David Goitein MD, Eytan Ben-Ami MD, Aviram Nissan MD, Jacob Schachter MD, Schlomo Schneebaum MD 

First published: 26 June 2017

J. Surg. Oncol.http://dx.doi.org/10.1002/jso.24744(2017)


Neadjuvant BRAF inhibition enables resection

Nature Reviews Clinical Oncology (2017)

 

doi:10.1038/nrclinonc.2017.106

Published online 11 July 2017


Int. J. Mol. Sci. 201718(7), 1508; doi: 10.3390/ijms18071508

Article

Cudraflavone C Induces Apoptosis of A375.S2 Melanoma Cells through Mitochondrial ROS Production and MAPK Activation

Chiang-Wen Lee 1,2,3,†, Feng-Lin Yen 4,5,†, Horng-Huey Ko 4, Shu-Yu Li 6, Yao-Chang Chiang 1,7, Ming-Hsueh Lee 8, Ming-Horng Tsai 9 and Lee-Fen Hsu 10,*

Received: 14 June 2017 / Accepted: 6 July 2017 / Published: 13 July 2017


International Journal of Molecular Sciences

Review Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma

Xian Yang Chan, Alamdeep Singh, Narin Osman and Terrence J. Piva

Received: 19 June 2017; Accepted: 12 July 2017; Published: 14 July 2017


Oncology Letters

Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma

Xiaowen Wu, Junya Yan, Jie Dai, Meng Ma, Huan Tang, Jiayi Yu, Tianxiao Xu, Huan Yu, Lu Si, Zhihong Chi, Xinan Sheng, Chuanliang Cui, Yan Kong, Jun Guo

Published online on: July 19, 2017     https://doi.org/10.3892/ol.2017.6608


Oncology Reports

Clinical significance of miR-138 in patients with malignant melanoma through targeting of PDK1 in the PI3K/AKT autophagy signaling pathway

Fanjun Meng, Yuxia Zhang, Xing Li, Juan Wang, Zhiyu Wang

Published online on: July 19, 2017     https://doi.org/10.3892/or.2017.5838


Clinical Cancer Research

PD-L1 expression and immune escape in melanoma resistance to MAPK inhibitors

Hojabr Kakavand, Robert V Rawson, Gulietta M Pupo, Jean Y H Yang, Alexander M Menzies, Matteo S. Carlino, Richard F. Kefford, Julie R Howle, Robyn Saw, John F. Thompson, James S Wilmott, Georgina V. Long, Richard A. Scolyer and Helen Rizos

DOI: 10.1158/1078-0432.CCR-16-1688 Published January 2017


JAMA Dermatology

Research Letter

July 26, 2017

Clinical Outcomes of Metastatic Melanoma Treated With Checkpoint Inhibitors and Multisite Radiotherapy

Jérôme Doyen, MD, PhD1Alexandra Picard, MD2Arash O. Naghavi, MD3; et alAntoine Thyss, MD4Thierry Passeron, MD, PhD2Jean-Philippe Lacour, MD, PhD2Henri Montaudié, MD2

JAMA Dermatol. Published online July 26, 2017. doi:10.1001/jamadermatol.2017.2222


JAMA Dermatology

Original Investigation

July 26, 2017

Risk Factors for Melanoma in Renal Transplant Recipients

Mona Ascha, MD1,2Mustafa S. Ascha, BS, MS3Joseph Tanenbaum, BA1; et alJeremy S. Bordeaux, MD, MPH4

JAMA Dermatol. Published online July 26, 2017. doi:10.1001/jamadermatol.2017.2291


JAMA Dermatology

Brief Report

July 26, 2017

Association of Incident Amelanotic Melanoma With Phenotypic Characteristics, MC1R Status, and Prior Amelanotic Melanoma

Steven Vernali, BA1Weston T. Waxweiler, MD1Patrick M. Dillon, MD2; et alPeter A. Kanetsky, MPH, PhD3Irene Orlow, PhD4Li Luo, PhD5Klaus J. Busam, MD4Anne Kricker, PhD6Bruce K. Armstrong, MBBS, DPhil6Hoda Anton-Culver, PhD7Stephen B. Gruber, MD, MPH, PhD8Richard P. Gallagher, MA9Roberto Zanetti, MD10Stefano Rosso, MD, MSc10Lidia Sacchetto, MSc10,11,12Terence Dwyer, MD13Anne E. Cust, PhD6David W. Ollila, MD14,15Colin B. Begg, PhD4Marianne Berwick, MPH, PhD5Nancy E. Thomas, MD, PhD1,14; for the GEM Study Group

JAMA Dermatol. Published online July 26, 2017. doi:10.1001/jamadermatol.2017.2444


International Journal of Oncology

Pristimerin effectively inhibits the malignant phenotypes of uveal melanoma cells by targeting NF??B pathway

Biao Zhang, Jing Zhang, Jingxuan Pan

Published online on: July 25, 2017     https://doi.org/10.3892/ijo.2017.4079